comprehensive -WSS

comprehensive

author：fashion 2025-09-02 08:13:24 - browse：95276

You’re reading the web edition of ASCO in 30 Seconds, STAT’s guide to the American Society of Clinical Oncology annual meeting. Sign up for the last day here.

ASCO is more than half done. There is free coffee on the exhibit floor. One booth barista said their team had made 1,400 espressos in a day. Everyone’s perspective is alternating between two verses from Smashing Pumpkins, who are, lest you forget, a Chicago band. “Today is the greatest day I’ve ever known.” Also: “I’ll burn my eyes out before I get out.”

What if sometimes cancer doctors could give less medicine?

Are cancer drugs more likely to be cures? Or could they instead turn cancer into a chronic disease, in which medicines keep tumors in check but patients have to deal with their side effects, both physical and financial, for the rest of their lives.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Alkermes shareholders re
Next article： Senators start work on Medicare physician payment reform

focus

leisure time

WSS

BioAge raises $170M for combination therapy with Zepbound

Pfizer is about to make a big push in cancer. Will investors listen?

PhRMA lawsuit over Medicare drug price negotiation tossed

Pfizer is about to make a big push in cancer. Will investors listen?

To avoid data mishandling cases, universities eye AI and other tools

Private equity deals in Medicare Advantage declines

focus

comprehensive

What if sometimes cancer doctors could give less medicine?

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

leisure time

Medicare details structure of new drug price negotiation program

Readout Newsletter: Beam, Prozac, "TechBio" and more

Dobbs anniversary: the lost opportunity of abortion as health care

BioAge raises $170M for combination therapy with Zepbound

Psychedelics group wrestles with new pharma identity

What we’ve learned from the Aduhelm mess

As demand for Covid shots wanes, Moderna seeks its next success

CDC advisory group OKs chikungunya vaccine

Moonlake's readout produced a cash windfall. Risks remain

Cholera vaccine supplies dangerously low, outbreaks surging

hotspot

Are embryos people? Reproductive medicine's future depends on the answer

Using force crossed my mind when examining a defiant young patient

Neuroscience renaissance leads to new crop of psychiatric drugs

Neuroscience renaissance leads to new crop of psychiatric drugs

Medicare Advantage isn’t working — for anyone

How digital tools helped lower hypertension in marginalized patients

focus

Wikipedia

leisure time

Wikipedia